Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene ther... Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunction and sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company was founded in 2020 and is headquartered in London, the United Kingdom. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 2.125 | 2.2 | 2.115 | 629231 | 2.14190428 | DE |
| 4 | -0.025 | -1.16279069767 | 2.15 | 2.2 | 2 | 866571 | 2.09794623 | DE |
| 12 | 0.275 | 14.8648648649 | 1.85 | 3.06 | 1.6825 | 2035637 | 2.25557688 | DE |
| 26 | 0.275 | 14.8648648649 | 1.85 | 3.06 | 1.25 | 2109968 | 2.06271647 | DE |
| 52 | 1.35 | 174.193548387 | 0.775 | 3.06 | 0.575 | 4066155 | 1.44095175 | DE |
| 156 | -0.925 | -30.3278688525 | 3.05 | 3.3 | 0.575 | 2127515 | 1.54158391 | DE |
| 260 | -7.125 | -77.027027027 | 9.25 | 13.25 | 0.575 | 1809207 | 1.98619765 | DE |
baltimorebullet
8分前
sctts
19分前
theorysuit
54分前
theorysuit
59分前
Ribo
1時間前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。